| Revision as of 15:33, 6 September 2007 editFT2 (talk | contribs)Edit filter managers, Administrators55,546 editsm →Eggan's work to date: retitle← Previous edit | Latest revision as of 17:45, 23 September 2024 edit undoCitation bot (talk | contribs)Bots5,436,264 edits Removed URL that duplicated identifier. Removed access-date with no URL. | Use this bot. Report bugs. | Suggested by Grimes2 | #UCB_webform 457/876 | ||
| (85 intermediate revisions by 65 users not shown) | |||
| Line 1: | Line 1: | ||
| {{Short description|American Professor of Stem Cell and Regenerative Biology}} | |||
| <!-- Please do not remove or change this AfD message until the issue is settled --> | |||
| {{Infobox scientist | |||
| <!-- The nomination page for this article already existed when this tag was added. If this was because the article had been nominated for deletion before, and you wish to renominate it, please replace "page=Kevin Eggan" with "page=Kevin Eggan (2nd nomination)" below before proceeding with the nomination. | |||
| |name = Kevin Eggan | |||
| -->{{AfDM|page=Kevin Eggan|date=2007 September 2|substed=yes}} | |||
| |image = | |||
| <!-- End of AfD message, feel free to edit beyond this point --> | |||
| |image_size = | |||
| |caption = Kevin Eggan | |||
| |birth_date = 1974 | |||
| |birth_place = ] | |||
| |death_date = | |||
| |death_place = | |||
| |residence = | |||
| |citizenship = | |||
| |nationality = American | |||
| |ethnicity = | |||
| |field = | |||
| |work_institutions = ] | |||
| |alma_mater = | |||
| |doctoral_advisor = Rudolf Jaenisch | |||
| |doctoral_students = | |||
| |known_for = ] | |||
| |author_abbrev_bot =|author_abbrev_zoo = | |||
| |influences = | |||
| |influenced = | |||
| |prizes = | |||
| |religion = |footnotes = |signature = | |||
| }} | |||
| '''Kevin Eggan''' (born |
'''Kevin Eggan''' (born 1974 in ]<ref name=bostonglobe>{{Cite news | title = ''Biologist Kevin Eggan: He sees stem cells as a solution'' | work = ] | date = 2006-07-03 | url = https://www.boston.com/news/science/articles/2006/07/03/he_sees_stem_cells_as_a_solution/ | access-date = 2007-09-04 | author = Andrew Rimas}}</ref>) is a Professor of Stem Cell and Regenerative Biology at ], known for his work in ] research (also known as "]"), and as a spokesperson for stem cell research in the United States. He was a 2006 recipient of a ] (sometimes nicknamed the "genius grant").<ref name="macarthur">{{Cite news | date = 2006-09-19 | title =B-N native awarded MacArthur 'genius' grant | work = ] via pantagraph.com | url = http://www.pantagraph.com/articles/2006/09/19/news/119224.txt}}</ref> In 2005, he was named to the ] ] ] as one of the top 35 innovators in the world under the age of 35.<ref>{{cite web|url=http://www.technologyreview.com/tr35/?year=2005 |title=2005 Young Innovators Under 35 |publisher=] | year=2005 | access-date=August 15, 2011}}</ref> | ||
| B-N native awarded MacArthur 'genius' grant | work = ] via pantagraph.com | url = http://www.pantagraph.com/articles/2006/09/19/news/119224.txt}}</ref> | |||
| ==Biography== | ==Biography== | ||
| ===Background and education=== | ===Background and education=== | ||
| Eggan grew up in ], the son of Chris and Larry Eggan and one of |
Eggan grew up in ], the son of Chris and Larry Eggan and one of five children,<ref>https://www.boston.com/news/science/articles/2006/07/03/he_sees_stem_cells_as_a_solution/ - "four sisters and a brother.</ref> his father being a math professor at ].<ref name="pantagraph"></ref> | ||
| After completing his |
After completing his bachelor's degree in ] at the ], he applied to medical school to become a doctor, but his doubts caused him to defer in favor of a two-year internship with drug company ]<ref name="bostonglobe" /> at the ]. In 1998 he applied to study for a Ph.D. in ] at the ], arriving there shortly after ] gained worldwide attention as the world's first ] domestic animal.<ref name="bostonglobe" /> | ||
| Eggan began to explore both this process and also the reasons that cloned animals often appeared to develop abnormally, with organ defects and immunological problems – his first contact with stem cell research. After finishing his PhD in 2002, Eggan split his time between a post-doctoral program with ] pioneer ] and a collaborative project with ], a ]–winning scientist at the ], as well as spending time at the ]. | Eggan began to explore both this process and also the reasons that cloned animals often appeared to develop abnormally, with organ defects and immunological problems – his first contact with stem cell research. After finishing his PhD in 2002, Eggan split his time between a post-doctoral program with ] pioneer ] and a collaborative project with ], a ]–winning scientist at the ], as well as spending time at the ]. | ||
| Line 17: | Line 39: | ||
| ===Stem cell research=== | ===Stem cell research=== | ||
| In August 2004, Eggan moved to ] in ], as a junior fellow, becoming an assistant professor of ] at their Stem Cell Institute ("HSCI") in 2005.<ref name="bostonglobe" /> At the time, stem cell research in the United States was threatened by political pressure due to concerns over the ethics of ], and research such as this was at risk of potentially being made illegal. Federal funding for stem cell research had recently been removed, and part of his role was to obtain private funding to replace it.<ref name="bostonglobe" /> Eggan took on a second role as the assistant investigator for ], a philanthropical medical research group.<ref name="NYT">{{Cite news |
In August 2004, Eggan moved to ] in ], as a junior fellow, becoming an assistant professor of ] at their Stem Cell Institute ("HSCI") in 2005.<ref name="bostonglobe" /> At the time, stem cell research in the United States was threatened by political pressure due to concerns over the ethics of ], and research such as this was at risk of potentially being made illegal. Federal funding for stem cell research had recently been removed, and part of his role was to obtain private funding to replace it.<ref name="bostonglobe" /> Eggan took on a second role as the assistant investigator for ], a philanthropical medical research group in ].<ref name="NYT">{{Cite news|author=Gina Kolata |work=] |date=2004-08-24 |access-date=2007-09-04 |title=Stem Cells: Promise, in Search of Results |url=https://www.nytimes.com/2004/08/24/science/24stem.html?pagewanted=1&ei=5090&en=18f7447019815f0d&ex=1251000000&partner=rssuserland |url-status=dead |archive-url=https://web.archive.org/web/20050831214115/http://www.nytimes.com/2004/08/24/science/24stem.html?pagewanted=1&ei=5090&en=18f7447019815f0d&ex=1251000000&partner=rssuserland |archive-date=August 31, 2005 |author-link=Gina Kolata }}</ref> | ||
| }}</ref> | |||
| Eggan's research goals at Harvard were to understand how ] works, and to make stem cells that carry genes for specific diseases such as ], ] (]), and ].<ref>{{Cite web | url = http://www.mcb.harvard.edu/NewsEvents/News/Eggan2.html | title = Kevin Eggan: Steps Towards Stemming Disease | |
Eggan's research goals at Harvard were to understand how ] works, and to make stem cells that carry genes for specific diseases such as ], ] (]), and ].<ref>{{Cite web | url = http://www.mcb.harvard.edu/NewsEvents/News/Eggan2.html | title = Kevin Eggan: Steps Towards Stemming Disease | website = Harvard University Department of Molecular and Cellular Biology News | access-date = 2007-09-04 | archive-url = https://web.archive.org/web/20070706062542/http://www.mcb.harvard.edu/NewsEvents/News/Eggan2.html | archive-date = 2007-07-06 | url-status = dead }}</ref><ref name=Forbes2>{{Cite news | title = P.C. Stem Cells; Kevin Eggan, 32 Cellular Biologist | url =https://www.forbes.com/2007/05/23/kevin-eggan-stem-cells-tech-cx_07rev_mh_0524eggan.html | author = Matthew Herper | work = ] | date = 2007-05-24 | access-date = 2007-09-04}}</ref> In 2006, following "more than two years of intensive ethical and scientific review", two groups of scientists at HSCI were granted permission to explore ] techniques to create disease-specific stem cell lines as an approach to various currently incurable conditions. Eggan was in charge of one of these two groups and senior author of their results;<ref name=Wash>{{Cite news | url = https://www.washingtonpost.com/wp-dyn/content/article/2005/08/22/AR2005082201198.html | author = Ceci Connolly | title = Stem Cell Advance Muddles Debate; Work May Stall Efforts To Lift Research Limits | newspaper = ] | date = 2005-08-23 | access-date = 2007-09-04}}</ref> a renowned co-director of HSCI ran the other.<ref name="HarvardGazette">{{Cite news | title = Approval granted for Harvard Stem Cell Institute researchers to attempt creation of disease-specific embryonic stem cell lines | url = http://www.news.harvard.edu/gazette/daily/2006/06/06-stemcell.html | date = 2006-06-06 | access-date = 2007-09-04 | work = The Harvard University Gazette |archive-url = https://web.archive.org/web/20070702115434/http://www.news.harvard.edu/gazette/daily/2006/06/06-stemcell.html <!-- Bot retrieved archive --> |archive-date = 2007-07-02}}</ref> The groups initially collaborated in researching ] before Eggan's group switched to work on ].<ref name="HarvardGazette" /> Harvard President ] called the approvals "a seminal event".<ref name="HarvardGazette" /> | ||
| Eggan also served as the Chief Scientific Officer of The New York Stem Cell Foundation. | |||
| === Work to date === | === Work to date === | ||
| Eggan's work |
Eggan's work {{As of|2007|lc=on}} has succeeded in developing a technique of merging stem and skin cells that has obtained considerable public attention as a possible avenue to avoid moral objections regarding stem cell research in the context of serious illness. It suggests that ultimately, treatment of serious illnesses and understanding of stem cell development may be possible to obtain without recourse to human embryos – a highly desirable state of affairs politically, given the concurrent controversy over stem cell research in the United States. | ||
| Eggan's team reported that they had created cells similar to human embryonic stem cells without destroying ], a major step toward someday possibly defusing the central objection to stem cell research.<ref>{{Cite news | title = Harvard scientists advance cell work; technique doesn't destroy embryos | |
Eggan's team reported that they had created cells similar to human embryonic stem cells without destroying ], a major step toward someday possibly defusing the central objection to stem cell research.<ref name=Wash /><ref>{{Cite news | title = Harvard scientists advance cell work; technique doesn't destroy embryos |author1=Gareth Cook |author2=Carey Goldberg | work = ] | url = https://www.boston.com/news/science/articles/2005/08/22/harvard_scientists_advance_cell_work/ | date = 2005-08-22 | access-date = 2007-09-04}}</ref><ref name="revolutionaries">{{Cite news | title = The Revolutionaries | url = https://www.forbes.com/2007/05/23/revolutionaries-innovators-science-tech-07rev_cx_ee_mn_0524rev_land.html |author1=Elisabeth Eaves |author2=Michael Noer | date = 2007-05-24 | access-date = 2007-09-04 | work = ]}}</ref> These discoveries sparked extensive debate in the ], with opponents of the use of embryonic stem cells from fetuses arguing that these or similar methods of creating stem cells from skin might be eventually used instead to satisfy the conflicting demands of medical research and morals.<ref name="nature" /> | ||
| : "Eggan's technique provides a window into exactly what happens to turn back the clock in cells during cloning--and, indeed, in the normal process of creating sperm, eggs and embryos. Somehow, aging is reversed, and old cells become young again. As Schatten puts it, the one-way freeway of life has an exit ramp. Understanding what happens when the cell is reprogrammed is one of the main goals of studying embryonic stem cells. But right now, the only way to solve that problem is to clone embryos, which is a difficult and expensive process.<ref>{{Cite news | author = Matthew Helper | title = Turning Skin Into Stem Cells | url = http://www.forbes.com/technology/2005/08/23/stem-cells-skin-cx_mh_0823cells.html | work = ] | date = 2005-08-23 | |
: "Eggan's technique provides a window into exactly what happens to turn back the clock in cells during cloning--and, indeed, in the normal process of creating sperm, eggs and embryos. Somehow, aging is reversed, and old cells become young again. As Schatten puts it, the one-way freeway of life has an exit ramp. Understanding what happens when the cell is reprogrammed is one of the main goals of studying embryonic stem cells. But right now, the only way to solve that problem is to clone embryos, which is a difficult and expensive process.<ref>{{Cite news | author = Matthew Helper | title = Turning Skin Into Stem Cells | url = https://www.forbes.com/technology/2005/08/23/stem-cells-skin-cx_mh_0823cells.html | archive-url = https://web.archive.org/web/20060114061719/http://www.forbes.com/technology/2005/08/23/stem-cells-skin-cx_mh_0823cells.html | url-status = dead | archive-date = January 14, 2006 | work = ] | date = 2005-08-23 | access-date = 2007-09-04}}</ref> | ||
| Eggan himself is cautious about his team's work, with an early stage 2005 profile in '']'' noting there was still much work to do: | Eggan himself is cautious about his team's work, with an early stage 2005 profile in '']'' noting there was still much work to do: | ||
| :The hybrids still contain two nuclei: one from a skin cell and one from an embryonic stem cell. So they have an abnormally high amount of DNA, and Eggan needs to work out how to remove the embryonic stem cell's DNA. Eggan adds that he has only just begun working with the hybrids, so it is not clear what they will or won't be able to do. "It's frustrating," Eggan says, "because they're implying that our work is a solution, which it is not yet. These are ideas in their most nascent stages." |
: The hybrids still contain two nuclei: one from a skin cell and one from an embryonic stem cell. So they have an abnormally high amount of DNA, and Eggan needs to work out how to remove the embryonic stem cell's DNA. Eggan adds that he has only just begun working with the hybrids, so it is not clear what they will or won't be able to do. "It's frustrating," Eggan says, "because they're implying that our work is a solution, which it is not yet. These are ideas in their most nascent stages."<ref name="nature">{{Cite journal | title = Stem-cell research: The rocky road to success Tackling the legal and ethical minefield associated with human embryonic stem-cell research is not for the faint-hearted | journal = ] | volume = 437 | pages = 185–186 | date = 2004-09-07 | author = Erika Check | doi = 10.1038/437185a | pmid = 16148905 | issue = 7056|s2cid=4391808 | doi-access = free }}</ref> | ||
| Tackling the legal and ethical minefield associated with human embryonic stem-cell research is not for the faint-hearted. | journal = ] | volume = 437 | pages = 185 - 186 | date = 2004-09-07 | author = Erika Check | accessdate = 2007-09-04}}</ref> | |||
| ===Work as spokesperson=== | ===Work as spokesperson=== | ||
| Forbes noted in Eggan's 2007 profile that: | Forbes noted in Eggan's 2007 profile that: | ||
| : "Eggan is also becoming one of science's more outspoken voices, defending the necessity of pursuing embryonic cell research through all available means as a way of understanding scourges ." |
: "Eggan is also becoming one of science's more outspoken voices, defending the necessity of pursuing embryonic cell research through all available means as a way of understanding scourges ."<ref name="revolutionaries" /> | ||
| ==Publications== | ==Publications== | ||
| Eggan's five most highly cited publications are: | Eggan's five most highly cited publications are: | ||
| *Humpherys, D; Eggan, K; Akutsu, H; Hochedlinger, K; Rideout, WM; Biniszkiewicz, D; Yanagimachi, R; Jaenisch, R. "Epigenetic instability in ES cells and cloned mice": '']'', 293 (5527): 95-97 JUL 6 2001, ''Times Cited: 288'' | * Humpherys, D; Eggan, K; Akutsu, H; Hochedlinger, K; Rideout, WM; Biniszkiewicz, D; Yanagimachi, R; Jaenisch, R. "Epigenetic instability in ES cells and cloned mice": '']'', 293 (5527): 95-97 JUL 6 2001, ''Times Cited: 288'' | ||
| * Rideout, WM; Eggan, K; Jaenisch, R. "Nuclear cloning and epigenetic reprogramming of the genome. '']'', 293 (5532): 1093-1098 (2001).'' Times Cited: 250'' | |||
| *Rideout, WM; |
* Eggan, K; Akutsu, H; Loring, J; Jackson-Grusby, L; Klemm, M; Rideout, WM; Yanagimachi, R; Jaenisch, R. "Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation," '']'', 98 (11): 6209-6214, May 22, 2001. Times Cited: 191 | ||
| ⚫ | * Humphreys, D; Eggan, K; Akutsu, H; Friedman, A; Hochedlinger, K; Yanagimachi, R; Lander, ES; Golub, TR; Jaenisch, R. "Abnormal gene expression in cloned mice derived from embryonic stem cell and cumulus cell nuclei." '']'', 99 (20): 12889-12894 (2002). ''Times Cited: 157'' | ||
| * |
* Bortvin, A; Eggan, K; Skaletsky, H; Akutsu, H; Berry, DL; Yanagimachi, R; Page, DC; Jaenisch, R. "Incomplete reactivation of Oct4-related genes in mouse embryos cloned from somatic nuclei" ''Development'', 130 (8): 1673-1680 (2003) ''Times Cited: 143'' | ||
| ⚫ | *Humphreys, D; Eggan, K; Akutsu, H; Friedman, A; Hochedlinger, K; Yanagimachi, R; Lander, ES; Golub, TR; Jaenisch, R. "Abnormal gene expression in cloned mice derived from embryonic stem cell and cumulus cell nuclei." '']'', 99 (20): 12889-12894 (2002). ''Times Cited: 157'' | ||
| *Bortvin, A; Eggan, K; Skaletsky, H; Akutsu, H; Berry, DL; Yanagimachi, R; Page, DC; Jaenisch, R. "Incomplete reactivation of Oct4-related genes in mouse embryos cloned from somatic nuclei" ''Development'', 130 (8): 1673-1680 (2003) ''Times Cited: 143'' | |||
| ==Awards== | ==Awards== | ||
| * |
* Winner of Harold M. Weintraub Graduate Student Award in 2003 sponsored by the Basic Sciences Division of the Fred Hutchinson Cancer Research Center<ref>{{Cite web |url=http://www.wi.mit.edu/news/archives/2003/rj_0402.html |title=Kevin Eggan Wins Harold M. Weintraub Grad Student Award |access-date=2007-09-02 |archive-url=https://web.archive.org/web/20060901171543/http://www.wi.mit.edu/news/archives/2003/rj_0402.html |archive-date=2006-09-01 |url-status=dead }}</ref> | ||
| *Honored in Popular Science's fourth annual "Brilliant 10" in 2005<ref>{{Cite news | url = |
* Honored in Popular Science's fourth annual "Brilliant 10" in 2005<ref>{{Cite news | url = https://www.usatoday.com/tech/science/2005-09-13-brilliant-minds_x.htm | title = 'Brilliant' minds honored | date = 2005-09-13 | access-date = 2007-09-04 | work = ] | author = Marissa Newhall}}</ref> | ||
| *Technology Review Magazine's "Innovator of the Year" in 2005 | * Technology Review Magazine's "Innovator of the Year" in 2005 | ||
| *MacArthur |
* ] 2006<ref name="macarthur" /> | ||
| * People Magazine's "Sexiest Genius" in 2006<ref>{{Cite news |date=November 27, 2006 |title=Feel the heat! |work=People Magazine |url=http://www.people.com/people/archive/article/0,,20059870,00.html |url-status=dead |archive-url=https://web.archive.org/web/20081030035456/https://people.com/people/archive/article/0,,20059870,00.html |archive-date=October 30, 2008}}</ref> | |||
| ==References== | ==References== | ||
| Line 63: | Line 81: | ||
| ==External links== | ==External links== | ||
| * | * | ||
| * | * | ||
| * | * | ||
| * | |||
| {{authority control}} | |||
| {{DEFAULTSORT:Eggan, Kevin}} | |||
| ] | |||
| ] | ] | ||
| ] | ] | ||
| ] | |||
| ] | |||
| ] | |||
| ] | |||
| ] | |||
| ] | |||
| ] | |||
Latest revision as of 17:45, 23 September 2024
American Professor of Stem Cell and Regenerative Biology| Kevin Eggan | |
|---|---|
| Born | 1974 Normal, Illinois |
| Nationality | American |
| Known for | stem cell |
| Scientific career | |
| Institutions | Harvard University |
| Doctoral advisor | Rudolf Jaenisch |
Kevin Eggan (born 1974 in Normal, Illinois) is a Professor of Stem Cell and Regenerative Biology at Harvard University, known for his work in stem cell research (also known as "therapeutic cloning"), and as a spokesperson for stem cell research in the United States. He was a 2006 recipient of a MacArthur Fellowship (sometimes nicknamed the "genius grant"). In 2005, he was named to the MIT Technology Review TR35 as one of the top 35 innovators in the world under the age of 35.
Biography
Background and education
Eggan grew up in Normal, Illinois, the son of Chris and Larry Eggan and one of five children, his father being a math professor at Illinois State University.
After completing his bachelor's degree in microbiology at the University of Illinois, he applied to medical school to become a doctor, but his doubts caused him to defer in favor of a two-year internship with drug company Amgen at the National Institutes of Health. In 1998 he applied to study for a Ph.D. in biology at the Massachusetts Institute of Technology, arriving there shortly after Dolly the Sheep gained worldwide attention as the world's first cloned domestic animal.
Eggan began to explore both this process and also the reasons that cloned animals often appeared to develop abnormally, with organ defects and immunological problems – his first contact with stem cell research. After finishing his PhD in 2002, Eggan split his time between a post-doctoral program with genetics pioneer Rudolf Jaenisch and a collaborative project with Richard Axel, a Nobel Prize–winning scientist at the Howard Hughes Medical Institute, as well as spending time at the University of Hawaii.
Stem cell research
In August 2004, Eggan moved to Harvard University in Cambridge, Massachusetts, as a junior fellow, becoming an assistant professor of Molecular & Cellular Biology at their Stem Cell Institute ("HSCI") in 2005. At the time, stem cell research in the United States was threatened by political pressure due to concerns over the ethics of human embryo research, and research such as this was at risk of potentially being made illegal. Federal funding for stem cell research had recently been removed, and part of his role was to obtain private funding to replace it. Eggan took on a second role as the assistant investigator for Stowers Institute for Medical Research, a philanthropical medical research group in Kansas City, Missouri.
Eggan's research goals at Harvard were to understand how nuclear transplantation works, and to make stem cells that carry genes for specific diseases such as Parkinson's disease, amyotrophic lateral sclerosis (Lou Gehrig's disease), and Alzheimer's. In 2006, following "more than two years of intensive ethical and scientific review", two groups of scientists at HSCI were granted permission to explore Somatic Cell Nuclear Transfer techniques to create disease-specific stem cell lines as an approach to various currently incurable conditions. Eggan was in charge of one of these two groups and senior author of their results; a renowned co-director of HSCI ran the other. The groups initially collaborated in researching diabetes before Eggan's group switched to work on neurodegenerative diseases. Harvard President Lawrence Summers called the approvals "a seminal event".
Eggan also served as the Chief Scientific Officer of The New York Stem Cell Foundation.
Work to date
Eggan's work as of 2007 has succeeded in developing a technique of merging stem and skin cells that has obtained considerable public attention as a possible avenue to avoid moral objections regarding stem cell research in the context of serious illness. It suggests that ultimately, treatment of serious illnesses and understanding of stem cell development may be possible to obtain without recourse to human embryos – a highly desirable state of affairs politically, given the concurrent controversy over stem cell research in the United States.
Eggan's team reported that they had created cells similar to human embryonic stem cells without destroying embryos, a major step toward someday possibly defusing the central objection to stem cell research. These discoveries sparked extensive debate in the United States Congress, with opponents of the use of embryonic stem cells from fetuses arguing that these or similar methods of creating stem cells from skin might be eventually used instead to satisfy the conflicting demands of medical research and morals.
- "Eggan's technique provides a window into exactly what happens to turn back the clock in cells during cloning--and, indeed, in the normal process of creating sperm, eggs and embryos. Somehow, aging is reversed, and old cells become young again. As Schatten puts it, the one-way freeway of life has an exit ramp. Understanding what happens when the cell is reprogrammed is one of the main goals of studying embryonic stem cells. But right now, the only way to solve that problem is to clone embryos, which is a difficult and expensive process.
Eggan himself is cautious about his team's work, with an early stage 2005 profile in Nature noting there was still much work to do:
- The hybrids still contain two nuclei: one from a skin cell and one from an embryonic stem cell. So they have an abnormally high amount of DNA, and Eggan needs to work out how to remove the embryonic stem cell's DNA. Eggan adds that he has only just begun working with the hybrids, so it is not clear what they will or won't be able to do. "It's frustrating," Eggan says, "because they're implying that our work is a solution, which it is not yet. These are ideas in their most nascent stages."
Work as spokesperson
Forbes noted in Eggan's 2007 profile that:
- "Eggan is also becoming one of science's more outspoken voices, defending the necessity of pursuing embryonic cell research through all available means as a way of understanding scourges ."
Publications
Eggan's five most highly cited publications are:
- Humpherys, D; Eggan, K; Akutsu, H; Hochedlinger, K; Rideout, WM; Biniszkiewicz, D; Yanagimachi, R; Jaenisch, R. "Epigenetic instability in ES cells and cloned mice": Science, 293 (5527): 95-97 JUL 6 2001, Times Cited: 288
- Rideout, WM; Eggan, K; Jaenisch, R. "Nuclear cloning and epigenetic reprogramming of the genome. Science, 293 (5532): 1093-1098 (2001). Times Cited: 250
- Eggan, K; Akutsu, H; Loring, J; Jackson-Grusby, L; Klemm, M; Rideout, WM; Yanagimachi, R; Jaenisch, R. "Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation," Proceedings of the National Academy of Sciences, 98 (11): 6209-6214, May 22, 2001. Times Cited: 191
- Humphreys, D; Eggan, K; Akutsu, H; Friedman, A; Hochedlinger, K; Yanagimachi, R; Lander, ES; Golub, TR; Jaenisch, R. "Abnormal gene expression in cloned mice derived from embryonic stem cell and cumulus cell nuclei." Proceedings of the National Academy of Sciences, 99 (20): 12889-12894 (2002). Times Cited: 157
- Bortvin, A; Eggan, K; Skaletsky, H; Akutsu, H; Berry, DL; Yanagimachi, R; Page, DC; Jaenisch, R. "Incomplete reactivation of Oct4-related genes in mouse embryos cloned from somatic nuclei" Development, 130 (8): 1673-1680 (2003) Times Cited: 143
Awards
- Winner of Harold M. Weintraub Graduate Student Award in 2003 sponsored by the Basic Sciences Division of the Fred Hutchinson Cancer Research Center
- Honored in Popular Science's fourth annual "Brilliant 10" in 2005
- Technology Review Magazine's "Innovator of the Year" in 2005
- MacArthur Fellows Program 2006
- People Magazine's "Sexiest Genius" in 2006
References
- ^ Andrew Rimas (2006-07-03). "Biologist Kevin Eggan: He sees stem cells as a solution". The Boston Globe. Retrieved 2007-09-04.
- ^ "B-N native awarded MacArthur 'genius' grant". Associated Press via pantagraph.com. 2006-09-19.
- "2005 Young Innovators Under 35". Technology Review. 2005. Retrieved August 15, 2011.
- https://www.boston.com/news/science/articles/2006/07/03/he_sees_stem_cells_as_a_solution/ - "four sisters and a brother.
- B-N native awarded MacArthur 'genius' grant
- Gina Kolata (2004-08-24). "Stem Cells: Promise, in Search of Results". The New York Times. Archived from the original on August 31, 2005. Retrieved 2007-09-04.
- "Kevin Eggan: Steps Towards Stemming Disease". Harvard University Department of Molecular and Cellular Biology News. Archived from the original on 2007-07-06. Retrieved 2007-09-04.
- Matthew Herper (2007-05-24). "P.C. Stem Cells; Kevin Eggan, 32 Cellular Biologist". Forbes. Retrieved 2007-09-04.
- ^ Ceci Connolly (2005-08-23). "Stem Cell Advance Muddles Debate; Work May Stall Efforts To Lift Research Limits". The Washington Post. Retrieved 2007-09-04.
- ^ "Approval granted for Harvard Stem Cell Institute researchers to attempt creation of disease-specific embryonic stem cell lines". The Harvard University Gazette. 2006-06-06. Archived from the original on 2007-07-02. Retrieved 2007-09-04.
- Gareth Cook; Carey Goldberg (2005-08-22). "Harvard scientists advance cell work; technique doesn't destroy embryos". The Boston Globe. Retrieved 2007-09-04.
- ^ Elisabeth Eaves; Michael Noer (2007-05-24). "The Revolutionaries". Forbes. Retrieved 2007-09-04.
- ^ Erika Check (2004-09-07). "Stem-cell research: The rocky road to success Tackling the legal and ethical minefield associated with human embryonic stem-cell research is not for the faint-hearted". Nature. 437 (7056): 185–186. doi:10.1038/437185a. PMID 16148905. S2CID 4391808.
- Matthew Helper (2005-08-23). "Turning Skin Into Stem Cells". Forbes. Archived from the original on January 14, 2006. Retrieved 2007-09-04.
- "Kevin Eggan Wins Harold M. Weintraub Grad Student Award". Archived from the original on 2006-09-01. Retrieved 2007-09-02.
- Marissa Newhall (2005-09-13). "'Brilliant' minds honored". USA Today. Retrieved 2007-09-04.
- "Feel the heat!". People Magazine. November 27, 2006. Archived from the original on October 30, 2008.
External links
- Kevin Eggan Lab
- Stowers Medical Institute
- Harvard Stem Cell Institute
- Nuclear Transfer into Mouse Oocytes